Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Liabilities and Shareholders Equity (2016 - 2025)

Traws Pharma (TRAW) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $12.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 39.25% to $12.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $72.1 million, a 5.28% increase, with the full-year FY2024 number at $25.0 million, up 10.05% from a year prior.
  • Liabilities and Shareholders Equity was $12.4 million for Q3 2025 at Traws Pharma, down from $15.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $60.0 million in Q3 2021 to a low of $8.9 million in Q3 2024.
  • A 5-year average of $32.9 million and a median of $30.5 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 177.58% in 2021, then plummeted 66.95% in 2024.
  • Traws Pharma's Liabilities and Shareholders Equity stood at $55.5 million in 2021, then dropped by 29.03% to $39.4 million in 2022, then tumbled by 42.39% to $22.7 million in 2023, then grew by 10.05% to $25.0 million in 2024, then crashed by 50.15% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Liabilities and Shareholders Equity are $12.4 million (Q3 2025), $15.6 million (Q2 2025), and $19.1 million (Q1 2025).